Drug-induced teratogenesis

Area of Science:

• Developmental Toxicology
• Pharmacology
• Teratology

Background:

• Teratogens are agents causing embryonic malformations, with risk influenced by multiple factors.
• Several therapeutic drugs exhibit teratogenic potential in animal models.
• Existing animal data may not fully predict human embryonic risks.

Purpose of the Study:

• To highlight the complex factors influencing teratogen-induced malformations.
• To emphasize the predictive value and limitations of animal studies for human teratogenicity.
• To underscore the necessity of clinical surveillance for drug safety in pregnancy.

Main Methods:

• Review of teratogenicity principles and influencing factors (agent, dose, genetics, developmental stage).
• Analysis of drug examples (salicylates, antibiotics) with demonstrated teratogenicity in animal models.
• Discussion of the interpretative challenges in extrapolating animal data to human risk assessment.

Main Results:

• Teratogenic probability is multifactorial, involving agent, dose, species, genetics, and embryonic stage.
• Some clinically used drugs are teratogenic in animals at therapeutic dose equivalents.
• Absence of experimental teratogenic effects does not confirm safety for human embryos.

Conclusions:

• Animal teratogenicity studies serve as crucial warnings but are not definitive for human risk.
• The thalidomide case illustrates how subtle or common malformations might mask teratogenic effects.
• Rigorous follow-up of infants born to mothers exposed to drugs during pregnancy is essential for safety evaluation.